➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Boehringer Ingelheim
Medtronic
McKinsey
Express Scripts

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,111,874

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,111,874
Title:Combination therapies for treatment of cancer
Abstract: Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
Inventor(s): Janes; Matthew Robert (Encinitas, CA), Patricelli; Matthew Peter (San Diego, CA), Li; Liansheng (San Diego, CA), Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA)
Assignee: Araxes Pharma LLC (San Diego, CA)
Application Number:14/858,766
Patent Claims:1. A method for treating a KRAS G12C mutant cancer, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to a subject in need thereof, wherein the KRAS G12C mutant modulating compound has the following structure (I'b): ##STR00689## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: X and Y are each independently N or CR.sup.6; Z is N or CR.sup.6a; L.sup.1 is a bond; L.sup.2 is a bond or alkylene; R' is R.sup.1 and R'' is R.sup.2c; or R' is H and R'' is R.sup.1; R.sup.1 is substituted or unsubstituted aryl or heteroaryl; R.sup.2a, R.sup.1b and R.sup.2C are each independently H, halo, hydroxyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.8 cycloalkyl or aryl; R.sup.3a and R.sup.3b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.4a and R.sup.4b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C.sub.1-C.sub.6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C.sub.1-C.sub.6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy; R.sup.6a is H or C.sub.1-C.sub.6 alkyl; represents a double or triple bond; Q is --C(.dbd.O)-, --C(.dbd.NR.sup.8')--, --NR.sup.8C(.dbd.O)-, --S(.dbd.O).sub.2- or --NR.sup.8S(.dbd.O).sub.2-; R.sup.8 is H, C.sub.1-C.sub.6 alkyl or hydroxylalkyl; R.sup.8' is H, --OH, --CN or C.sub.1-C.sub.6 alkyl; and when is a double bond then R.sup.9 and R.sup.10 are each independently H, cyano, carboxyl, C.sub.1-C.sub.6alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R.sup.9 and R.sup.10 join to form a carbocyclic or heterocyclic ring, provided at least one of X, Y and Z is N, wherein the KRAS mutant cancer is a pancreatic cancer, a colorectal cancer or a lung cancer.

2. The method of claim 1, wherein the additional therapeutic agent is a phosphatidylinositol-3 kinase (PI3K) inhibitor.

3. The method of claim 2, wherein the phosphatidylinositol kinase (PI3K) inhibitor is GDC0941, MLN1117, BYL719 (Alpelisib) or BKM120 (Buparlisib).

4. The method of claim 1, wherein the additional therapeutic agent is a protein kinase inhibitor.

5. The method of claim 4, wherein the protein kinase inhibitor is Afatinib, Axitinib, Bevacizumab, Bostutinib, Cetuximab, Crizotinib, Dasatinib, Erlotinib, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Ibrutinib, Nilotinib, Panitumumab, Pazopanib, Pegaptanib, Ranibizumab, Ruxolitinib, Sorafenib, Sunitinib, SU6656, Trastuzumab, Tofacitinib, Vandetanib or Vemurafenib.

6. A method for inducing apoptosis in a cell population comprising a KRAS G12C mutant protein, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to the cell population, wherein the KRAS G12C mutant modulating compound has the following structure (I'b): ##STR00690## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: X and Y are each independently N or CR.sup.6; Z is N or CR.sup.6a; L.sup.1 is a bond; L.sup.2 is a bond or alkylene; R' is R.sup.1 and R'' is R.sup.2c; or R' is H and R'' is R.sup.1; R.sup.1 is substituted or unsubstituted aryl or heteroaryl; R.sup.2a, R.sup.2band R.sup.2C are each independently H, halo, hydroxyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.8 cycloalkyl or aryl; R.sup.3a and R.sup.3b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.4a and R.sup.4b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C.sub.1-C.sub.6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C.sub.1-C.sub.6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy; R.sup.6a is H or C.sub.1-C.sub.6 alkyl; represents a double or triple bond; Q is --C(.dbd.O)--, --C(.dbd.NR.sup.8')-, --NR.sup.8C(.dbd.O)-, --S(.dbd.O).sub.2- or --NR.sup.8S(.dbd.O).sub.2-; R.sup.8 is H, C.sub.1-C.sub.6 alkyl or hydroxylalkyl; R.sup.8' is H, --OH, --CN or C.sub.1-C.sub.6 alkyl; and when is a double bond then R.sup.9 and R.sup.10 are each independently H, cyano, carboxyl, C.sub.1-C.sub.6alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R.sup.9 and R.sup.10 join to form a carbocyclic or heterocyclic ring, provided at least one of X, Y and Z is N.

7. A method for inhibiting G12C mutant protein in a subject, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to the subject, wherein the KRAS G12C mutant modulating compound has the following structure (I'b): ##STR00691## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: X and Y are each independently N or CR.sup.6; Z is N or CR.sup.6a; L.sup.1 is a bond; L.sup.2 is a bond or alkylene; R' is R.sup.1 and R'' is R.sup.2c; or R' is H and R'' is R.sup.1; R.sup.1 is substituted or unsubstituted aryl or heteroaryl; R.sup.2a, R.sup.2b and R.sup.2C are each independently H, halo, hydroxyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.8 cycloalkyl or aryl; R.sup.3a and R.sup.3b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.4a and R.sup.4b are, at each occurrence, independently H, --OH, --NH.sub.2, --CO.sub.2H, halo, cyano, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl; R.sup.6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C.sub.1-C.sub.6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C.sub.1-C.sub.6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy; R.sup.6a is H or C.sub.1-C.sub.6 alkyl; represents a double or triple bond; Q is --C(.dbd.O)--, --C(.dbd.NR.sup.8')-, --NR.sup.8C(.dbd.O)-, --S(.dbd.O).sub.2- or --NR.sup.8S(.dbd.O).sub.2-; R.sup.8 is H, C.sub.1-C.sub.6 alkyl or hydroxylalkyl; R.sup.8 is H, --OH, --CN or C.sub.1-C.sub.6 alkyl; and when is a double bond then R.sup.9 and R.sup.10 are each independently H, cyano, carboxyl, C.sub.1-C.sub.6alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R.sup.9 and R.sup.10 join to form a carbocyclic or heterocyclic ring, provided at least one of X, Y and Z is N.

8. The method of claim 1, 6 or 7, wherein: represents a double bond; Q is --C(.dbd.O)--, --C(.dbd.NR.sup.8')-, --NR.sup.8C(.dbd.O)-, --S(.dbd.O).sub.2- or --NR.sup.8S(.dbd.O).sub.2-; R.sup.8 is H, C.sub.1-C.sub.6 alkyl or hydroxylalkyl; R.sup.8' is H, --OH, --CN or C.sub.1-C.sub.6alkyl; and R.sup.9 and R.sup.10 are each independently H, cyano, C.sub.1-C.sub.6alkyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R.sup.9 and R.sup.10 join to form a carbocyclic or heterocyclic ring.

9. The method of claim 8, wherein Q is --C(.dbd.O)--, and R.sup.9 and R.sup.10 are each H.

10. The method of claim 1, 6 or 7, wherein the G12C mutant modulating compound has the following structure: ##STR00692##

11. The method of claim 1, 6 or 7, wherein X and Z are N, and Y is CR.sup.6.

12. The method of claim 1, 6 or 7, wherein R.sup.1 is substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl.

13. The method of claim 1, 6 or 7, wherein R.sup.1 has one of the following structures: ##STR00693## ##STR00694## ##STR00695## ##STR00696## ##STR00697##

14. The method of claim 1, 6 or 7, wherein R.sup.2a and R.sup.2b are each independently H or halo.

15. The method of claim 1, 6 or 7, wherein the KRAS G12C mutant modulating compound has one of the following structures: ##STR00698## ##STR00699##

16. The method of claim 1, 6 or 7, wherein the additional therapeutic agent is an epidermal growth factor receptor (EGFR) inhibitor, phosphatidylinositol kinase (PI3K) inhibitor, insulin-like growth factor receptor (IGF1R) inhibitor, Janus kinase (JAK) inhibitor, a Met kinase (MET) inhibitor, a SRC family kinase (SFK) inhibitor, a mitogen-activated protein kinase (MEK) inhibitor, an extracellular-signal-regulated kinase (ERK) inhibitor, mechanistic target of rapamycin (mTOR) inhibitor, a topoisomerase inhibitor, a taxane, an anti-metabolite agent, an alkylating agent or a taxane.

17. The method of claim 16, wherein the additional therapeutic agent is an epidermal growth factor receptor (EGFR) inhibitor.

18. The method of claim 17, wherein the epidermal growth factor receptor (EGFR) inhibitor is Erlotinib, Afatinib or Iressa.

19. The method of claim 1, 6 or 7 wherein the compound and the additional therapeutic agent are co-administered.

20. The method of claim 1, 6 or 7 wherein the compound and the additional therapeutic agent are separately administered.

Details for Patent 10,111,874

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ⤷  Try it Free Araxes Pharma LLC (San Diego, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Moodys
Express Scripts
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.